Overall rank by patents
#44,596
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
ARC holds 5 US patents across 5 technology areas, rank #44,596 of 50,000 tracked assignees.
ARC Medical Inc. has been granted 5 US utility patents between 2023 and 2025, placing ARC Medical Inc. at rank #44,596 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.2 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, ARC Medical Inc. is one of the more focused assignees in the PatentsView dataset. By volume, ARC sits between Aquavit Pharmaceuticals, Inc. (5 patents, rank #44,592) and Arcelormittal WIRE France (5 patents, rank #44,600) - the closest US assignees by grant volume. The composite Innovation Score of 45.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ARC Medical Inc.'s 19.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ARC Medical Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
AQUAVIT PHARMACEUTICALS, INC.
5 patents
AR PATENTS, LLC
5 patents
AR, LLC
5 patents
ARAVIVE BIOLOGICS, INC.
5 patents
ARCADIA POWER, INC.
5 patents
ARCADIS U.S., INC.
5 patents
ARCELORMITTAL TUBULAR PRODUCTS LUXEMBOURG S.A.
5 patents
ARCELORMITTAL WIRE FRANCE
5 patents
ARC Medical Inc.
5 patents
What this shows ARC holds 5 patents at rank #44,596, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,596 in granted patent volume.
Other assignees with the most granted patents in ARC's primary technology class.
ARC's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 23% higher than 77% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 2 | 40.0% |
| 2024 | 1 | 20.0% |
| 2025 | 2 | 40.0% |
Top 5 of 5 technology areas
Overall rank by patents
#44,596
Across all tracked assignees
45.6 out of 100
How to use this portfolio
ARC's 5 grants land it in the top 23% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.